Ann: Investor Update, page-31

They've been plodding along with similar cash levels for years. Trials and regulatory approval applications well underway. The likelihood of any immediate CR per above unlikely IMO. Suspect the company will wait for further positive trial results and regulatory approvals to prompt share price higher and execute a CR in the medium term. Look forward to the further 2Q19 data releases - the tendon results with CelGro particularly. I had the ATI procedure years ago on a poorly attached surgical tendon repair and it was a life-saver. The potential of these types of treatment versus traditional surgical intervention are poles apart as patients are more likely to tell you than clinicians...